PEN * Stock Overview
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Penumbra, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4,218.53 |
| 52 Week High | US$5,621.42 |
| 52 Week Low | US$3,679.98 |
| Beta | 0.53 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 33.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| PEN * | MX Medical Equipment | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how PEN * performed against the MX Medical Equipment industry.
Return vs Market: Insufficient data to determine how PEN * performed against the MX Market.
Price Volatility
| PEN * volatility | |
|---|---|
| PEN * Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: PEN * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PEN *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 4,200 | Adam Elsesser | www.penumbrainc.com |
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands.
Penumbra, Inc. Fundamentals Summary
| PEN * fundamental statistics | |
|---|---|
| Market cap | Mex$142.67b |
| Earnings (TTM) | Mex$1.50b |
| Revenue (TTM) | Mex$17.42b |
95.3x
P/E Ratio8.2x
P/S RatioIs PEN * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PEN * income statement (TTM) | |
|---|---|
| Revenue | US$1.06b |
| Cost of Revenue | US$375.88m |
| Gross Profit | US$682.64m |
| Other Expenses | US$591.69m |
| Earnings | US$90.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.35 |
| Gross Margin | 64.49% |
| Net Profit Margin | 8.59% |
| Debt/Equity Ratio | 0% |
How did PEN * perform over the long term?
See historical performance and comparison